Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.43 |
| ▸ | CCR4 | P51679 | 11/20 | 0.43 |
| ▸ | CD38 | P28907 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4205431 | 0.87 | NPSR1 (0.43) | EPHX2CCR4ALDH1A1 | |
| SCHEMBL13780307 | 0.86 | CCR4 (0.44) | EPHX2CCR4CD38 | |
| SCHEMBL13780314 | 0.85 | CCR4 (0.46) | EPHX2CCR4CD38 | |
| SCHEMBL13780157 | 0.84 | EPHX2 (0.45) | EPHX2CCR4 | |
| SCHEMBL4201718 | 0.84 | KDM4E (0.40) | EPHX2CCR4KDM4EALDH1A1POLB | |
| SCHEMBL13780308 | 0.84 | CCR4 (0.40) | EPHX2CCR4CD38 | |
| SCHEMBL4975648 | 0.83 | CCR4 (0.44) | EPHX2CCR4ALDH1A1 | |
| SCHEMBL13780152 | 0.82 | EPHX2 (0.52) | EPHX2CCR4 | |
| SCHEMBL13780154 | 0.82 | EPHX2 (0.52) | EPHX2CCR4 | |
| SCHEMBL13780107 | 0.81 | EPHX2 (0.51) | EPHX2CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | CCR4, CCR1, HRH4 | EPHX2 265/4885CCR4 1/4885CD38 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.